Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Frickhofen, N. Young (1989)
Persistent parvovirus B19 infections in humans.Microbial pathogenesis, 7 5
O. Corsi, A. Azzi, M. Morfini, R. Fanci, P. Ferrini (1988)
Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentratesJournal of Medical Virology, 25
G. Kurtzman, K. Ozawa, B. Cohen, G. Hanson, R. Oseas, N. Young (1987)
Chronic bone marrow failure due to persistent B19 parvovirus infection.The New England journal of medicine, 317 5
C. Jones (1963)
REGIONAL CURARISATION. ANAESTHESIA FOR SURGERY OF THE KNEE-JOINT.Lancet, 2 7306
N. Frickhofen, J. Abkowitz, M. Safford, J. Berry, J. Antunez-de-Mayolo, A. Astrow, Robert Cohen, I. Halperin, L. King, D. Mintzer, B. Cohen, N. Young (1990)
Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.Annals of internal medicine, 113 12
P. Mortimer, N. Luban, J. Kelleher, B. Cohen (1983)
TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATESThe Lancet, 322
Foreman Foreman, Oakhill Oakhill, Caul Caul (1988)
Parvovirus‐Associated thrombocytopenic purpuraLancet, 2
M. Williams, B. Cohen, A. Beddall, K. Pasi, P. Mortimer, F. Hill (1990)
Transmission of Human Parvovirus B19 by Coagulation Factor ConcentratesVox Sanguinis, 58
Azzi Azzi, Macchia Macchia, Favre Favre, Zakrzewska Zakrzewska, Bartolomei Corsi Bartolomei Corsi (1989)
Aplastic crisis caused by B19 parvovirus infection in a child during induction therapy for acute lymphoblastic leukemiaHaematologica, 74
0 1992 Wiley-Liss, Inc. etiological agent of erythema infectiousurn but it is also known as a cause of arthropaty, febrile illness, aplastic crisis, and recently also thrombocytopenia [2]. Persistent B 19 infection may occur in immunodeficient patients, leading to chronic anemia 13-51. The seroconversion for B 19 virus develops between 5 and 7 years of life in about 30% of normal children and a similar prevalence of IgG specific for B19 has been observed in blood donors [6]. Viremia has been observed in only 1 out of 10,000 normal people. Because of the very large number of blood donors (up to 20,00030,000) participating in the plasma pool for industrial fractionation, clotting factor concentrates are at high risk of transmitting B19 virus to the recipients. The prevalence of B19-IgG in hemophiliacs infused before 1985 with concentrates not subjected to virucidal methods is very high: 90-95% [6,7]. Furthermore, B19 is very resistant to virucidal methods developed so far: seroconversion against B 19 has been detected in previously untreated hemophilic patients after the first treatment with dry-, wet-, and steam-heated factor VIII concentrates [6,8]. It is well known that the solventldetergent method destroys only the lipid-enveloped viruses. B 19 virus has
American Journal of Hematology – Wiley
Published: Feb 1, 1992
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.